Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Dr. Reddy's introduces Debiopharm prostate cancer medication in India

PBR Staff Writer Published 10 December 2012

Dr. Reddy's Laboratories has launched Swiss-based Debiopharm's Pamorelin LA , indicated for locally advanced or metastatic, hormone-dependent prostate cancer, in India.

Pursuant to the deal signed between the two companies, Dr. Reddy's has exclusive commercialization rights for the product, which will be exported from Debio Recherche Pharmaceutique, in India.

The Indian company will initially make the product available to urologists and oncologists across the country.

Debiopharm Group president and founder Rolland-Yves Mauvernay said, "This major step enables us to implement our strategy in one of the most important markets in Asia. This is only the logical continuation to a harmonious working relationship shared with Dr. Reddy's over the years."

Pamorelin LA contains Triptorelin, an agonist analogue of the natural gonadotropin-releasing hormone, as the active ingredient.

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.